Financial Analysis
Filing-based analysis. Market pricing is not included. Fundamentals from SEC filings; economic data from FRED and the BLS. About our data
Filing evidence summary
Caution evidenceCoverage 4/5 core metricsOperating margin changed -52.1 percentage points from the prior annual period.
Backward-looking filed evidence under visible rules - not a rating, forecast or investment advice. Missing data is never scored.
Evidence signals
- Operating margin compressed
Operating margin changed -52.1 percentage points from the prior annual period.
Why this surfaced
Direction threshold: more than +1 percentage point constructive; below -1 point caution. Period end 2025-12-31.
- Free cash flow was negative
Latest reported free cash flow was -$80M.
Why this surfaced
Free cash flow = operating cash flow minus capital expenditures; positive is supporting evidence, not a valuation conclusion. Period end 2025-12-31.
- 4 filing risk checks flagged
Flagged areas: Earnings quality, Solvency & liquidity, Dilution.
Why this surfaced
The full financial analysis shows each value, threshold, and sector limitation.
- Revenue was broadly stable
Latest reported annual revenue changed +1.1% from the prior reported annual observation.
Why this surfaced
Direction threshold: above +2% constructive; below -2% caution; otherwise monitor. This is not labeled one-year growth when filing periods have a gap. Period end 2025-12-31.
Core trend metrics
Hover a tile for its exact definition; the Statements tab carries per-cell filing citations.
Where to look next
Risk checks
- Earnings quality
- Solvency & liquidity
- Dilution
Financial movement
- Cash→ flat
- Long-term debt→ flat
- Inventory→ flat
- Receivables→ flat
- Current assets→ flat
Source & freshness
- Source
- SEC EDGAR XBRL
- Fetched
- 2026-09-06
- Latest period end
- 2025-12-31
- Filings
- EDGAR ↗
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Reportable Segment$139M100.0%+2.4% yoy
Members sum to the consolidated $139M for this period.
- Product$92.9Mshare n/a+16.6% yoy
- Consumable And Other Products$75.1Mshare n/a+8.4% yoy
- Simoa Product Revenue$71Mshare n/a-10.9% yoy
- Service And Other Revenue$44.2Mshare n/a-13.7% yoy
- Simoa Service And Other Revenue$32.4Mshare n/a-36.8% yoy
- Research Services$26Mshare n/a-31.6% yoy
- Spatial Product Revenue$21.9Mshare n/ano prior
- Instrument Products$17.9Mshare n/a+70.4% yoy
- +5 more members in the filing
member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.
- Product$25.5Mshare n/a+22.9% yoy
- Consumable And Other Products$21.4Mshare n/a+18.0% yoy
- Simoa Product Revenue$16.8Mshare n/a-19.0% yoy
- Service And Other Revenue$10.4Mshare n/a+17.6% yoy
- Spatial Product Revenue$8.68Mshare n/ano prior
- Simoa Service And Other Revenue$6.68Mshare n/a-24.3% yoy
- +6 more members in the filing
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
Peer percentiles
latest fiscal year ending 2025-12-31 · among 4,058 US-listed filers · 318 in Healthcare| Metric | Value | vs all filers | vs sector |
|---|---|---|---|
Revenue latest fiscal-year revenue as filed | $139M | 30thof 3,301 bottom third | 41stof 291 middle third |
Revenue growth latest fiscal-year revenue vs the prior fiscal year | 1.1% | 33rdof 3,137 bottom third | 26thof 277 bottom third |
Gross margin gross profit ÷ revenue | 46.8% | 62ndof 1,603 middle third | 35thof 212 middle third |
Operating margin operating income ÷ revenue | -90.4% | 17thof 2,819 bottom third | 19thof 280 bottom third |
Net margin net income ÷ revenue | -77.1% | 16thof 3,263 bottom third | 20thof 290 bottom third |
Free-cash-flow margin (operating cash flow − |capex|) ÷ revenue | -57.5% | 15thof 2,679 bottom third | 18thof 261 bottom third |
Return on equity net income ÷ stockholders' equity (positive equity only) | -36.2% | 22ndof 3,577 bottom third | 35thof 291 middle third |
Stock comp ÷ revenue stock-based compensation ÷ revenue · lower is ranked higher | 14.9% | 20thof 2,895 bottom third | 20thof 272 bottom third |
Days sales outstanding receivables ÷ revenue × 365 · lower is ranked higher | 79 days | 20thof 2,398 bottom third | 19thof 266 bottom third |
Each filer's latest fiscal year as stored by the nightly crawl; fiscal year ends differ across the universe. A metric ranks only filers for which it is computable from filed facts. Ties split; a rank reads "better than N% of filers" in the metric's own direction. Descriptive and educational, not a rating.
Earnings quality
Not available for QTRX yet: Earnings-quality fields arrive with this issuer's next re-crawl (sec_screen_v6)..
Point-in-time ledger
Not available for QTRX yet: The point-in-time ledger arrives with this issuer's next re-crawl (sec_screen_v6)..
Notes by disclosure type
Not available for QTRX yet: no footnote text blocks on file for this filer in the ingested DERA files.
Fundamentals from SEC EDGAR. Scores, the DCF, and every model shown are educational analysis, not investment advice or price predictions.